Oncology
Malignancies
2
Pipeline Programs↗
28
Active Trials↗
26
Companies Involved↗
Malignancies is an early-stage landscape with 2 programs across 26 companies. The most active players are Bristol-Myers Squibb, Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 12
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 100% of 2 pipeline programs.
Analysis
Trial Status
119
clinical trials
Completed49 · 41%
Terminated23 · 19%
Recruiting16 · 13%
Withdrawn9 · 8%
Unknown status9 · 8%
Active, not recruiting5 · 4%
Other8 · 7%
Clinical Trials
Trial Activity
119 trials
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Recruiting·—·Phase 1·NCT02203903·50 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)